CRVSCorvus Pharmaceuticals, Inc.

HealthcareUSD
$14.74

The financials

Corvus Pharmaceuticals, Inc. by the numbers

Corvus Pharmaceuticals, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$19M−$10Mn/a
Net income−$18M−$8.0Mn/a
Diluted EPS−$0.19−$0.10n/a

Biotechnology

Ranks #104 of 145 by Smart Score

Compare peers
WVE-3.4%
Wave Life Sciences Ltd.
MGTX-0.60%
MeiraGTx Holdings plc
EYPT-4.8%
EyePoint, Inc.
MNKD+2.3%
MannKind Corporation
SVRA+3.4%
Savara Inc.
AVLN-3.7%
Avalyn Pharma Inc.